Inogen price target lowered to $191 from $280 at Needham. Needham analyst Mike lowered his price target on Inogen to $191 after its Q4 results saying the quarter had some flaws including slower domestic B2B sales and a decline in its operating margin. The analyst maintains his Strong Buy rating on the shares however and believes that Inogen is “no longer priced for perfection”, anticipating the company to continue to generate strong growth given the “ongoing sales force expansion, new product cycle, and the market shift to Portable Oxygen Concentrators.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.